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Background:  In pts at high surgical risk, transcatheter aortic valve replacement (TAVR) with a self-expanding bioprosthesis is associated 
with improved 1-y survival compared with surgical aortic valve replacement (SAVR). Since elderly pts may be more concerned with quality 
of life than prolonged survival, we compared health status outcomes for pts treated with either self-expanding TAVR or SAVR.
methods:  Between 2011 and 2012, 795 high-risk pts with severe AS were randomized to TAVR or SAVR in the CoreValve US Trial. Health 
status was assessed at baseline and 1, 6, and 12-mos using the Kansas City Cardiomyopathy Questionnaire (KCCQ), SF-12, and EQ-5D; 
growth curve models were used to examine changes over time.
results:  Over the 1-y follow-up period, disease-specific and generic health status improved substantially for both treatment groups. At 
1-mo, there was a significant interaction between the benefit of TAVR over SAVR and access site. Among pts eligible for iliofemoral (IF) 
access, there was a clinically relevant early benefit with TAVR. Among the non-IF cohort; however, most health status measures were 
similar for TAVR and SAVR, although there was a trend toward early benefit with TAVR on the SF-12 physical health scale.
conclusion:  Health status improved substantially in high-risk pts treated with either self-expanding TAVR or SAVR. TAVR via IF route 
was associated with better early health status compared with SAVR, but there was no apparent health status benefit with non-IF TAVR 
compared with SAVR.
 
